About this trial
Neuropathic pain affects 6-10% of the global population and is poorly managed - current drug treatments succeed in only \~25% of patients. Spinal cord stimulation (SCS) modulates pain by electrically stimulating spinal dorsal column fibres. The newer paresthesia-free mode (PF-SCS, 500-10,000 Hz) appears more effective and tolerable than traditional paresthesia-based SCS, with superior outcomes shown in the SENZA-RCT. All promising PF-SCS studies have been unblinded, making them susceptible to placebo effects. The one blinded RCT that exists had significant methodological flaws (no washout period, single baseline measurement) that biased results toward the null. A blinded, multi-centre, crossover RCT in 90 patients comparing 6 weeks of active PF-SCS vs. 6 weeks of placebo stimulation, with a 2-week washout in between - designed to correct the flaws of the prior trial and definitively establish whether PF-SCS works beyond placebo.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years or older
Severe NP in the axial locations (neck and back) and/ or the limbs
Undergoing an SCS implantation with a PF device
Disqualifiers
Previously implanted with an SCS device
Not fluent in English
Unable to provide written informed consent
Trial design
Crossover
Treatments tested in this trial
Paresthesia-free spinal cord stimulation
DeviceAt the beginning of the PF-SCS phase, the unblinded trial nurse will set the stimulator to provide active stimulation \[500-1200 Hz at 70% of the perception amplitude - usually between 3 to 5 mA\], which will remain constant for the 6-week duration of this period.
Treatment groups
Trial outcomes
Primary outcomes
Evaluate the analgesic outcomes from PF-SCS against outcomes from placebo
PAcStim will compare the effect of 6 weeks of treatment with PF-SCS and placebo on Pain intensity, measured using the 0 to 10 pain numeric rating scale
Secondary outcomes
Evaluate the impact of PF-SCS on daily activity and sleep duration
The secondary goals are to evaluate the impact of PF-SCS on daily activity and sleep duration using wearable actigraphy monitors
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: